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Background and Objectives This study was conducted by the International
Consortium for Blood Safety (ICBS) to identify high-quality test kits for detection of
hepatitis B virus (HBV) surface antigen (HBsAg) for the beneﬁt of developing
countries.
Materials and Methods The 70 HBsAg test kits from around the world were evalu-
ated comparatively for their clinical sensitivity, analytical sensitivity, sensitivity to
HBV genotypes and HBsAg subtypes, and speciﬁcity using 394 (146 clinical, 48
analytical and 200 negative) ICBS Master Panel members of diverse geographical
origin comprising the major HBV genotypes A-F and the HBsAg subtypes adw2,4,
adr and ayw1-4.
Results Seventeen HBsAg enzyme immunoassay (EIA) kits had high analytical sen-
sitivity <0Æ13 IU⁄ml, showed 100% diagnostic sensitivity, and were even sensitive
for the various HBV variants tested. An additional six test kits had high sensitivity
(<0Æ13 IU⁄ml) but missed HBsAg mutants and⁄or showed reduced sensitivity to cer-
tain HBV genotypes. Twenty HBsAg EIA kits were in the sensitivity range of 0Æ13–
1I U⁄ml. The other eight EIAs and the 19 rapid assays had analytical sensitivities of
1t o> 4I U⁄ml. These assays were falsely negative for 1–4 clinical samples and 17 of
these test kits showed genotype dependent sensitivity reduction. Analytical sensi-
tivities for HBsAg of >1 IU⁄ml signiﬁcantly reduce the length of the HBsAg positive
period which renders them less reliable for detecting HBsAg in asymptomatic HBV
infections. Reduced sensitivity for HBsAg with genetic diversity of HBV occurred
with genotypes⁄subtypes D⁄ayw3,E⁄ayw4,F⁄adw4 and by S gene mutants. Speci-
ﬁcity of the HBsAg assays was ‡99Æ5% in 57 test kits and 96Æ4–99Æ0% in the remain-
ing test kits.
Conclusion Diagnostic efﬁcacy of the evaluated HBsAg test kits differed substan-
tially. Laboratories should therefore be aware of the analytical sensitivity for HBsAg
and check for the relevant HBV variants circulating in the relevant population.
Key words: HBsAg sensitivity, HBV genotypes, HBV subtypes, ICBS,S gene mutants.
Introduction
Hepatitis B virus (HBV) is the most common, chronic viral
infection globally. Approximately two billion people
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403worldwide are affected and about 350 million have active
chronic HBV infection [1,2]. In highly endemic areas such
as East and Southeast Asia, sub-Saharan Africa, and parts
of South America, over 8% of the population are chronic
carriers of HBV [1]. 80% of adults with chronic HBV infec-
tion will have no indication that they have been infected.
Due to the often silent nature of the disease, testing for
HBV is imperative for public health, particularly for blood
screening. Undetected acute infections and chronic carriers
with low level viraemia facilitate spread of HBV. Hepatitis
B surface antigen (HBsAg) is a key marker for screening
and laboratory diagnosis of HBV infection and the ﬁrst
serological marker to appear during the course of HBV
infection. HBsAg sensitivity depends on the detection
threshold of immunoassays. The lower the detection limit
for HBsAg, the smaller the diagnostic ‘window phase’ in
early infection [3,4] and the higher the capability to detect
the smallest amounts of HBsAg in asymptomatic patients
and chronic carriers [5]. Thus, regulatory requirements for
HBsAg are expressed as minimum analytical sensitivity to a
certain HBsAg reference standard concentration [6,7].
Because of the genetic diversity of HBV, sensitivity of
HBsAg assays may also be dependent on antigenic varia-
tion of HBsAg. In fact, some HBsAg mutants that emerge
after selection by immune pressure can escape detection by
commercial HBsAg assays [4,8–11]. In addition, there is
natural heterogeneity in HBV due to genotype and subtype
diversity. There are eight different HBV genotypes, A-H,
based on DNA sequence. Within these are nine serological
subtypes characterized by a limited number of amino acid
substitutes in the ‘a’ determinant of the S gene, i.e., ayw1,
ayw2, ayw3, ayw4, ayr, adw2, adw4, adrq+ and adrq) [12–
19]. The HBV genotypes have a distinct geographical distri-
bution [17,18]. Genotypes A and D have global distribution,
genotypes B and C predominate in East and Southeast Asia,
genotype E is in West Africa, genotype F is found in the
indigenous population of Central and South America,
genotype G has been found in France and USA [20], and
genotype H is restricted to Central and South America
[15,21]. On the other hand, the standards used for calibra-
tion of the HBsAg test kits are based on genotype A subtype
ad [22,23]. Furthermore, reduced sensitivity with HBV vari-
ants is likely to be detected only quantitatively, i.e., the
immunoassay is capable of detecting them at high HBV
concentrations but not at low antigen concentrations. Thus,
laboratories testing blood samples for HBV are increasingly
required to recognize the different HBV genotypes and sub-
types and to detect very low levels of hepatitis B surface
antigen. It has therefore been recommended that Regula-
tory Authorities devise panels for kit evaluation that
include HBsAg-reactive specimens with subtypes and
genotypes from their local regions [22]. To meet these
needs, the International Consortium for Blood Safety (ICBS)
established HBsAg Master Panels which include panel
members comprising the major HBV genotypes A-F and
HBsAg subtypes adw2-4, ayw1-4 and adr. These samples
were collected from blood banks around the world to evalu-
ate HBsAg assays for sensitivity. This will assist national
authorities in the developing world to make informed
decisions regarding the choice of assays to be used and
therefore help in establishing a sustainable supply of
affordable, good quality, screening reagents.
Materials and methods
Specimens
Plasma units were collected by the ICBS from blood banks
around the world to establish test panels that would be used
to evaluate the performance of 70 HBsAg assays. The estab-
lishment of the ICBS hepatitis B virus master panels was
completed in March 2005. Detailed characterization of the
panels is shown in tables on the ICBS website [24].
Sequencing, genotyping, and subtyping of the panel was
conducted at the Hepatitis Laboratory Branch, Division of
Viral Hepatitis, Centers for Disease Control and Prevention
(CDC), Atlanta, GA, as described by Purdy et al. [19]. The
sequences, genotyping, and subtyping were also indepen-
dently performed in the Department of Medical Sciences,
Toshiba General Hospital, Tokyo, Japan, by the method
described by Takahashi et al. [25]. Further characterization
of the samples was done at the Paul-Ehrlich-Institut (PEI),
Langen, Germany. The HBsAg content of the samples was
measured by the quantitative Architect HBsAg (Abbott
GmbH & Co. KG, Wiesbaden, Germany) in international
units per ml (IU⁄ml) which also has been found to be corre-
lated with the level of serum HBV-DNA [26]. The serologi-
cal proﬁle of the HBsAg positive samples was determined
by testing for anti-HBc, anti-HBc IgM, anti-HBs, anti-HBe
and HBeAg as shown on the ICBS website [24]. All samples
were anti-HIV 1⁄2 (Architect HIV Ag⁄Ab, Abbott GmbH &
Co. KG) and anti-HCV negative (Murex HCV v4.0, Abbott
Murex Biotech Ltd., Dartford, UK and Architect HCV, Ab-
bott GmbH & Co. KG). The large-scale ﬁll of the ICBS Panel
was done under Good Manufacturing Practice compliant
conditions at the Institut fu ¨r Biotechnologische Diagnostik
mbH (GBD), Berlin, Germany.
ICBS HBsAg Clinical Panel
Clinical (diagnostic) sensitivity was evaluated by the ICBS
HBsAg Clinical Panel consisting of 146 HBsAg positive
specimens. All samples were also anti-HBc positive by the
Architect Anti-HBc assay (Abbott GmbH & Co. KG Wiesba-
den, Germany). The panel is geographically diverse, includ-
ing the major HBV genotypes and subtypes as displayed in
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in Table S1 in the supporting information accessible in the
online version of this article). The serological proﬁle of the
ICBS HBsAg Clinical Panel is given on the ICBS webpage
[24].
ICBS HBsAg Quantitative Panel
The ICBS HBsAg Quantitative Panel consists of eight HBV
genotype and HBsAg subtype combinations as shown in
Table 1. Amino acid alignment of the ‘a’ determinant of the
S gene of the samples is shown in Table 2. The sequences
were compared with the reference sequence for genotype A
subtype adw2 of Norder et al. [13]. A dilution series was
created from each sample by preparing six HBsAg concen-
trations in the range of 4, 1, 0Æ25, 0Æ125, 0Æ063, 0Æ031 IU⁄ml
using deﬁbrinated normal human plasma as the diluent
(negative for anti-HBs, HBsAg, anti-HCV anti-HIV 1⁄2,
HCV-RNA and HIV-1 RNA). This concentration range was
chosen to cover the detection limits of high and low sensi-
tive HBsAg assays as estimated in reference [22]. The dilu-
ent served as the negative control in each dilution series.
Quantiﬁcation of the HBsAg concentration was done by the
quantitative Architect HBsAg (Abbott GmbH & Co. KG)
relative to the 2nd HBsAg WHO international standard
(00⁄588, 33 IU⁄ml). Specimens with concentration values
<0Æ05 IU⁄ml were considered non-reactive, and specimens
with concentration values ‡0Æ05 IU⁄ml were considered
reactive by the criteria of Architect HBsAg. Each dilution
series of the eight genotype samples in the ICBS Quantita-
tive Panel was linear (r
2 = 1) in the given concentration
range of 0Æ05–4 IU⁄ml.
PEI HBsAg ad standard
The Paul-Ehrlich-Institut (PEI) HBsAg standard has been
included as an independent HBsAg reference prepara-
tion which had been characterized by a biochemical,
Table 1 HBV genotypes and HBsAg subtypes in the ICBS HBsAg Clinical Panel and ICBS HBsAg Quantitative Panel
ICBS HBsAg Clinical Panel
HBV
genotype
HBsAg
subtype
Country of origin
Brazil Egypt Ivory Coast Jordan South Africa Tunisia USA Vietnam Total no. of samples
A adw2 12 2 2 8 24
ayw1 5 1 6
adw4 1 1
ayw2 1 1
B adw2 1 10 2 13
ayw1 11 6 1 7
C adw2 1 1
adr 64 1 0
D ayw2 6 1 7 6 2 22
ayw3 1 34
ayw4 1 1
adw2 2 1 3
E ayw4 29 1 30
F adw4 12 11 3
Total 34 3 34 10 2 8 33 22 146
ICBS HBsAg Quantitative Panel
Sample ID Country of origin HBV genotype HBV subtype
220 Jordan A adw2
546 Vietnam B ayw1
570 Vietnam B adw2
516 Vietnam C adr
93 Tunisia D ayw2
318 Brazil D ayw3
246 Ivory Coast E ayw4
713 Brazil (Manaus) F adw4
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ad has a unitage of 1000 PEI units per ml which are trace-
able to the 2nd WHO HBsAg international standard. One IU
corresponds to 0Æ43 PEI units [22]. Serial dilutions of the
PEI standard for HBsAg were made in fetal calf serum. The
dilution range tested for each assay was from 1Æ0 PEI-U⁄ml
in two-fold steps down to 0Æ0020 PEI-U⁄ml.
ICBS Negative Panel
The Negative Panel includes 200 samples from the Ameri-
can Red Cross, DC, USA. All plasma units were tested and
found negative for markers of HBV (HBsAg and anti-HBc),
HCV (anti-HCV, HCV-RNA), HIV (anti-HIV 1⁄2, HIV-1
RNA), HTLV (anti-HTLV I⁄II), syphilis and Parvovirus B19
(DNA PCR) infection.
Assays
All HBsAg test kits brought to the attention of ICBS were
purchased from the open market and not directly from the
manufacturers. This was to ensure that test kits chosen for
evaluation were from routine production runs, thus
avoiding any possible biased selection by manufacturers
for batches of higher sensitivity that might not reﬂect the
usual performance of the assay.
The 70 HBsAg assays evaluated included 51 enzyme
immunoassays (EIA) and 19 rapid assays. Information
regarding the assays used in this study including product
name, manufacturer, test format, test structure, catalogue
numbers, and manufacturers’ contact information are
shown on the ICBS website [24].
Laboratory testing
Starting June 2005 the 70 HBsAg test kits were evalu-
ated, in the order they were received, by the ICBS Test
Kits Evaluation Centre at the Paul-Ehrlich-Institut (PEI)
in Langen, Germany. The assays were carried out and
interpreted according to the instructions for use provided
by each manufacturer. One person carried out all the
testing for a single assay. Specimens discordant from the
assigned pedigreed status were repeated in duplicate and
the repeat reactive rate was taken for sensitivity and
speciﬁcity calculation. With the rapid assays, discordant
results were read independently by a second person.
Table 2 Amino acid alignment of the ‘a’ determinant of the S gene of the eight samples of the ICBS HBsAg Quantitative Panel
A⁄adw 100 QGMLPVCPLI
110 120 130 140
PGSTTTSTGP CKTCTTPAQG NSMFPSCCCT KPTDGNCTCI
A⁄adw2 #220 100 ·········· ·········· ·········· ··········· ···········
B⁄ayw1 #546 100 ·········· ···S······ ·R········ T········· ········· ·
B⁄adw2 #570 100 ·········· ···S······ ·········· T········· ········· ·
C⁄adr #516 100 ·········L ··TS······ ·····I···· T········· ········· ·
D⁄ayw2 #93 100 ·········· ···S······· R········· T··Y······ ··S·······
D⁄ayw3 #318 100 ·········· ···S···V··· R····TV·· T··Y······ ··S·······
E⁄ayw4 #246 100 ·········· ···S······· R····I··· T········S ··S·······
F⁄adw4 #713 100 ·········L ··········· K····L··· T········S ··S·······
A⁄adw 150 PIPSSWAFAK
160 170 180 190
YLWEWASVRF SWLSLLVPFV QWFVGLSPTV WLSAIWMMWY
A⁄adw2 #220 150 ·········· ······· ··· ·········· ·········· ··········
B⁄ayw1 #546 150 ·········· ······· ··· ·········· ·········· ···V···I··
B⁄adw2 #570 150 ·········· ······ · ··· ·········· ·········· ···V······
C⁄adr #516 150 ·········R F····· · ··· ·········· ·········· ···V······
D⁄ayw2 #93 150 ········G· F······A·· ·········· ·········· ···V······
D⁄ayw3 #318 150 ········G· F······A·· ·········· ·········· ···V······
E⁄ayw4 #246 150 ·········· ········ ·· ·········· ·········· ··········
F⁄adw4 #713 150 ·······LG· ···· ···A·· ·······Q·· ··C······· ··LV···I··
The dots represent the positions which are the same as the prototype A⁄adw sequence as referenced in [13]. Genotype and subtype speciﬁc residues
according to references [14,15,18] are shown. Residues determining the genotype and subtype according to reference [19] are bold.D⁄ayw3 substitution at
positions 118 and 128 are underlined. The amino acids shown are described with one letter abbreviation according to: IUPAC-IUB Joint Commission on
Biochemical Nomenclature.
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sidered equivocal.
Calculation of analytical sensitivity, diagnostic
sensitivity and speciﬁcity
For determination of the analytical sensitivity, the intercept
of the dilution series with the assay’s cut-off point was cal-
culated by linear interpolation between the last positive
and the ﬁrst negative point. Also, conversion of the assay’s
results into IU⁄ml was done by linear interpolation. The
results for the PEI HBsAg ad standard and for the ICBS
Quantitative Panel were expressed in IU⁄ml relative to the
2nd WHO HBsAg international standard. Sensitivity reduc-
tion for the various genotypes and subtypes was calculated
for each assay as a factor relative to the result for genotype
A subtype adw2 in the same assay. Diagnostic sensitivity
and speciﬁcity were calculated according to standard pro-
cedures [27,28]. To summarize, diagnostic sensitivity was
calculated as the number of HBsAg positives of an assay
divided by the total number of HBsAg conﬁrmed positive
panel specimens tested, multiplied by 100. Test speciﬁcity
was calculated as the number of HBsAg negatives found by
an assay and divided by the total number of conﬁrmed
HBsAg negative panel specimens tested, multiplied by 100.
Correlation of HBsAg kinetics in seroconversion
with analytical sensitivity for HBsAg
Thirty-two commercially available HBV seroconversion
panels were analysed for the kinetics of HBsAg concentra-
tion and for the time needed to detect speciﬁed HBsAg con-
centrations of 0Æ02, 0Æ05, 0Æ13, 0Æ5, 1Æ0 and 4Æ0I U⁄ml. The
panels were from SeraCare Life Science (West Bridgewater,
MA) and Zeptometrix Inc. (Franklin, MA). The HBsAg con-
centrations of the panel members were determined with the
Architect HBsAg (Abbott GmbH & Co. KG) and the PRISM
HBsAg (Abbott). To describe the kinetics of HBsAg detec-
tion, an exponential function (exp(a*t)b)), where t = day,
was ﬁtted to each of the 32 seroconversion panels (proce-
dure ‘nls’ from R) [29]. To estimate the time until detection
of the pre-speciﬁed HBsAg levels, the inverse of the ﬁtted
regression function was used.
Results
Analytical sensitivity of the 70 HBsAg test kits
Figure 1 shows the range in analytical sensitivities of the
70 HBsAg tests with the ICBS HBsAg Quantitative Panel
genotype A subtype adw2 and the PEI HBsAg standard sub-
type ad (1000 PEI-U⁄ml). The range of sensitivity between
the most sensitive test kit and the least sensitive HBsAg
devices was 0Æ021 IU⁄ml to >2Æ33 IU⁄ml with the PEI
ad standard and 0Æ013 IU⁄ml to >4 IU⁄ml with the ICBS
Quantitative Panel. This represents a >300-fold difference
between the most sensitive assay and the least sensitive
devices. Twenty-three HBsAg test kits had analytical sensi-
tivities <0Æ13 IU⁄ml, which represents the current state of
the art for blood screening in the European Union (EU)
[3,4,6]. Twenty EIAs were between 0Æ013 IU⁄ml and
1I U⁄ml, seven EIAs had sensitivities >1 IU⁄ml, and one
EIA could not detect any of the HBsAg concentrations
tested (>4 IU⁄ml). Regarding the 19 HBsAg rapid assays
tested, one could detect 1Æ5I U⁄ml, two rapid assays had
sensitivities of 1Æ7–4 IU⁄ml, three rapid assays barely
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Fig. 1 Analytical sensitivities of the 70 HBsAg test kits evaluated.
aAnalytical Sensitivities for each assay are expressed as IU⁄ml relative to the 2nd HBsAg
WHO international standard.
bThe 70 HBsAg test kits were sorted according to their analytical sensitivity with the PEI HBsAg ad standard.
cEach symbol in
ﬁgure represents the detection limit of an HBsAg kits as shown in Table S2 in the electronic version of the article.
dDetection limits > 2Æ3I U⁄ml are shown
as 2Æ5I U⁄ml.
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the ICBS standard dilutions as positive, i.e., these tests can
only detect undiluted specimens with HBsAg levels of over
4I U⁄ml (The detailed results are shown in Table S2 in the
supporting information accessible in the online version of
this article). Figure 1 also shows that in the assays evalu-
ated the ICBS genotype A subtype adw2 (panel #220) corre-
lated well with the PEI HBsAg ad standard. The sensitivity
of the eight different HBV geno-⁄subtypes in the different
assays relative to genotype A subtype adw2 for the 51 EIAs
is displayed in Fig. 2. Thirty test kits showed even sensitiv-
ity for all genotypes⁄subtypes studied, 17 HBsAg test kits
showed reduced sensitivity concomitantly for the geno-
types⁄subtypes D⁄ayw3,E ⁄ayw4 and F⁄adw4, one assay
showed sensitivity reduction for genotype⁄subtype D⁄ayw3
and another assay showed reduced sensitivity for the geno-
types⁄subtypes E⁄ayw4 and F⁄adw4 only. The rapid assays
did not give continuous values and were not included in
Fig. 2 but one rapid assay also showed the pattern of con-
comitant sensitivity reduction for genotypes⁄subtypes
D⁄ayw3,E⁄ayw4 and F⁄adw4. Seventeen rapid assays and
four EIAs were too insensitive in the range of the dilution
series tested (£4I U⁄ml) to judge for quantitative differ-
ences. The degree of the geno-⁄subtype dependent
sensitivity reductions ranged from 4 to 50 for D⁄ayw3 and
from 2 to 20 for both, E⁄ayw4 and F⁄adw4. In case of the
sensitivity reductions occurring, singly for D⁄ayw3, or for
E⁄ayw4 and F⁄adw4, the sensitivity reduction ranged from
2t o3 .
Correlation of HBsAg kinetics in seroconversion
with analytical sensitivity for HBsAg
The HBsAg concentration increases exponentially with the
time of the follow-up samples during seroconversion.
Inversely, the time (days) needed for detection of HBsAg
during seroconversion increases logarithmically with the
detection limit for HBsAg. This is shown in Fig. 3 averaged
over the 32 seroconversion panels tested (The detailed
results are available in Table S3 in the supporting informa-
tion accessible in the online version of this article). The day
delay in HBsAg detection at speciﬁed assays¢ analytical
sensitivities was compared to the ﬁrst positive HBsAg
detection at 0Æ02 IU⁄ml. By this, HBsAg detection limits of
0Æ05 IU⁄ml, 0Æ13 IU⁄ml, 0Æ5I U⁄ml, 1 IU⁄ml, 2 IU⁄ml, and
4I U⁄ml correspond to a mean day delay in detection of
HBsAg assays of 3Æ5 (range 1Æ6–7Æ2), 7Æ1 (range 3Æ4–14Æ6),
12Æ2 (range 5Æ9–25Æ1), 14Æ8 (range 7Æ1–30Æ6), 17Æ5 (range
8Æ4–36 IU⁄ml), and 20Æ1 (range 9Æ7–41Æ4) days, respectively.
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ing to the Architect HBsAg (Abbott), this represents a mean
day delay of 3Æ6 (range 1Æ8–7Æ4), 8Æ7 (range 4Æ3–17Æ9), 11Æ3
(range 5Æ5–23Æ4), 14 (range 4Æ9–32Æ5) and 16Æ6 (range 8Æ1–
34Æ2) days, respectively.
Diagnostic sensitivity with the ICBS HBsAg Clinical
Panel
Diagnostic sensitivity with the ICBS HBsAg Clinical Panel
in the 70 test kits evaluated is shown in Table 3 (Further
information is available in Table S4 in the supporting
information accessible in the online version of this article).
Eighteen EIA test kits were 100% positive, the other 33 EIAs
were false negative in 1–4 samples (sensitivity range 99Æ3–
97Æ3%), and the 19 rapid assays had 2–8 false negatives
(sensitivity range 99Æ3–94Æ5%). The false negatives were
mainly with the ICBS Clinical Panel samples #1125, #1135,
#1010, #1039 and #1015. This was seen with some HBsAg
test kits even if the detection limit actually should have
been able to detect the HBsAg concentration in these
samples: Sixteen test kits were negative with at least one of
the samples #1125, #1135, and #1010, two EIAs and two
rapid assays failed to detect HBsAg in sample #1039
E⁄ayw4 (72 IU⁄ml), and four rapid assays did not detect
sample #1015. Other HBsAg test kits were positive with the
same ﬁve samples but showed signiﬁcantly reduced sensi-
tivity. Table 3 shows the reduction factors. There was
20-fold reduced sensitivity with mutant T131I (#1010), 13-
to 120-fold reduced sensitivity with mutant Q101H
(#1039), and mutant S143L (#1015) revealed a marked
500- to >1000-fold sensitivity reduction in two EIAs which
would have been negative if it had not been for the high
HBsAg concentration in the sample (>8000 IU⁄ml). More-
over, some rapid assays revealed deﬁciencies in detection
of more samples. One rapid assay was false negative with
samples #1105 B⁄ayw1 (19Æ16 IU⁄ml), #1121, B⁄adw2
(35Æ14 IU⁄ml), #1115 B⁄adw2 (50Æ77 IU⁄ml), and #1106
B⁄ayw1 (50Æ97 IU⁄ml). Another rapid assay did not detect
sample #1032 E⁄ayw4 (21Æ91 IU⁄ml). Four other rapid
assays were equivocal with sample #1105 B⁄ayw1
(19Æ16 IU⁄ml).
Table 3 Relative sensitivity reduction in HBsAg assays with the problematic samples of the ICBS HBsAg Clinical Panel
Test
format
Number of
assays (n)
Clinical
sensitivity (%)
ICBS HBsAg Clinical Panel samples
Sample ID #1125 #1135 #1010 #1039 #1015
Genotype⁄subtype B⁄adw2 B⁄adw2 D⁄ayw2 E⁄ayw4 D⁄ayw2
Mutation M133L P105R T131I Q101H S143L
HBsAg concentration
(IU⁄ml) 0Æ21 0Æ22 0Æ36 72 >8000
Analytical
sensitivity
(IU⁄ml)
a
Number of
false neg. (n) Relative sensitivity reduction
b (n⁄n)
c
EIA 18 100 0Æ02–0Æ13 0 0 0 0 0 500 to >1000
2⁄18
EIA 5 99Æ32–98Æ63 0Æ07–0Æ13 1–2 1–25
4⁄5
1–25
4⁄5
002 0
1⁄5
EIA 9 99Æ32–98Æ63 0Æ14–0Æ22 1–2 1–25
6⁄9
1–25
7⁄9
000
EIA 6 98Æ63–97Æ26 0Æ23–0Æ36 2–3 BDL
4⁄6
BDL
6⁄6
20
1⁄6
120 0
EIA 13 98Æ63–97Æ26 0Æ39–2Æ3 2–4 BDL
12⁄13
BDL
12⁄13
BDL
11 ⁄13
13–120
2⁄13
0
Rapid 19 98Æ63–94Æ52 1Æ7–2Æ3 2–8 BDL
19⁄19
BDL
19⁄19
BDL
18⁄19
2⁄19 4⁄19
Detailed data is available in Table S4 in the electronic version of this article.
aDetection limit see Table S2.
bApproximated relative factor in sensitivity reduction compared to ICBS A⁄adw2 (panel #220).
cNumber of assays reacting with sensitivity reduction out of total assays in the line.
BDL, below detection limit.
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Quantitative Panel members and of the HBsAg
mutant samples in the ICBS HBsAg Clinical Panel
The amino acid alignment of the S gene of the eight geno-
type⁄subtype samples of the ICBS HBsAg Quantitative
Panel is shown in Table 2. The primary structure for the
various genotypes is within the expected range of the refer-
ence sequences [13,16], but genotype⁄subtype D⁄ayw3
sample #318 shows a particular A118V⁄T128V double sub-
stitution characteristic for a speciﬁc D⁄ayw3 strain [14].
Genotypes⁄subtypes D⁄ayw3,E⁄ayw4, and F⁄adw4, which
were detected with reduced sensitivity in some assays, share
a substitution at position 127, i.e., P127T for the ayw3 sub-
type and T127I⁄L speciﬁc for E⁄ayw4 and F⁄adw4.
Moreover, E⁄ayw4 and F⁄adw4 have the genotype speciﬁc
P140T residue.
Amino acid alignment of the S gene of the ﬁve samples
of the ICBS Clinical Panel which caused reduced sensitivity
in some test kits revealed the following mutations in the ‘a’
determinant as shown in Table 4: M133L in sample #1125,
P105R in sample #1135, T131I in sample #1010, T⁄S143L
in sample #1015, and Q101H in sample #1039.
Speciﬁcity
Speciﬁcity in the ICBS Negative Panel of 200 negative
samples was 100% in 50 assays, seven assays showed one
non-speciﬁc result with speciﬁcity of 99Æ5%, and nine
assays showed more than one non-speciﬁc: 99Æ0% (n = 4),
98Æ5% (n = 1), 97Æ0% (n = 2) and 96Æ4% (n = 2). Four
assays, though ordered, were not supplied in sufﬁcient
quantity to determine speciﬁcity.
Discussion
The results of the performance evaluation of 70 HBsAg test
kits show that the diagnostic efﬁcacy of the tests differed
signiﬁcantly. The sensitivity range between the most sensi-
tive HBsAg devices and the least sensitive HBsAg assays
was more than 300-fold. Enzyme immunoassays (EIA), in
general, performed better than rapid assays. However, also
within the EIAs there was a signiﬁcant 200-fold variation
in sensitivity; moreover, ﬁve EIAs were less sensitive than
rapid assays. Combining the results for analytical sensitiv-
ity, clinical sensitivity, and sensitivity for HBV variants,
resulted in the following overall performance picture. A
group of 17 assays showed high analytical sensitivity of
<0Æ13 IU⁄ml comparable to the level of current blood
screening tests in the EU [3,4,8], were 100% sensitive in the
ICBS Clinical Panel, and were even sensitive for all HBV
variants tested. A second group of 6 EIA test kits showed
also high sensitivity of <0Æ13 IU⁄ml [8]. However ﬁve of
these six assays missed HBsAg mutants in the ICBS Clinical
Panel, two of which also showed signiﬁcant reduced sensi-
tivity for genotypes D⁄ayw3,E ⁄ayw4 and F⁄adw4 in the
ICBS Quantitative Panel, and another assay showed geno-
type dependent sensitivity reduction only. A third group of
Table 4 Amino acid alignment of the HBsAg mutant samples of the ICBS HBsAg Clinical Panel which caused reduced sensitivity in some HBsAg test kits
A⁄adw2
110 120 130 140 150
QGMLPVCPLI PGSTTTSTGP CKTCTTPAQG NSMFPSCCCT KPTDGNCTCI
B⁄adw2 #1125 100 ·········· ·········· ·········· T·L······· ··········
B⁄adw2 #1135 100 ····R···I· ·········· ·········· T········· ··········
D⁄ayw2 #1010 100 ·········· ···S······ ·R········ I··Y······ ··S·······
D⁄ayw2 #1015 100 ·········· ···S······ ·R········ T··Y······ ··L·······
E⁄ayw4 #1039 100 ·H········ ····S····· ·R····L··· T········S ··S·······
A⁄adw2
160 170
PIPSSWAFAK YLWEWASVRF SWLS
B⁄adw2 #1125 150 ·········KF ········· ····
B⁄adw2 #1135 150 ·········K ·········· ····
D⁄ayw2 #1010 150 ········GK F······A·· ····
D⁄ayw2 #1015 150 ·········KF ······A·· ····
E⁄ayw4 #1039 150 ········GK F······A·· ····
The dots represent the positions which are the same as the sequence in reference [13] but the variations speciﬁc for the respective genotypes accordingt o
reference [13] are shown. Mutations are shown in bold and underlined. The amino acids shown are described with one letter abbreviation according to:
IUPAC-IUB Joint Commission on Biochemical Nomenclature.
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1I U⁄ml, but did not detect all clinical samples at HBsAg
concentrations of 0Æ21–0Æ36 IU⁄ml due to mutations in the
S gene and⁄or because of low sensitivity. Furthermore, 16
assays in this group also showed signiﬁcant reduced sensi-
tivity for HBV genotypes⁄subtypes D⁄ayw3,E ⁄ayw4 and
F⁄adw4. A fourth group of eight EIA HBsAg tests and all 19
rapid assays studied were of poor sensitivity (>1 IU⁄ml).
Thirteen rapid assays and one EIA of the third group did
not detect any of the dilution series at 4 IU⁄ml; and 5 of
these 13 rapid assays revealed difﬁculties in detecting
HBsAg concentrations around 20 IU⁄ml in the ICBS Clini-
cal Panel.
Correlation of HBsAg seroconversion kinetics with ana-
lytical assay sensitivities reveals that the detectable HBsAg
positive period at detection limits of 1 IU⁄ml and 4 IU⁄ml
is reduced to levels not deemed suitable for screening blood
donations. The delay in detection of HBsAg at analytical
sensitivities of 1 IU⁄ml and 4 IU⁄ml averages to 11Æ3 days
and 16Æ6 days, respectively, relative to an HBsAg assay
detection limit of 0Æ05 IU⁄ml, which reﬂects the current
blood screening standard, e.g. in the EU. Assuming a simi-
lar delay in HBsAg detection in the peak-off viremia of
HBV, this would correspond to a total reduction of the
detectable HBsAg positive period of 22Æ6–33Æ2 days,
respectively following HBV infection. Based on a total
detectable HBsAg EIA positive period of 31 days in asymp-
tomatic patients (ALT < 100 IU⁄ml) and of 82 days in
symptomatic (ALT > 100 IU⁄ml) HBV infection [30] this
means virtually no detectable HBsAg in asymptomatic HBV
infection and a considerable shortening of the detectable
HBsAg period of 82 days in symptomatic HBV infection
[30]. This would make it also improbable that low level
HBsAg is reliably detected positive in late resolving phase
and chronic carriers. With respect to the rapid tests in gen-
eral, it appears that further development is necessary to
achieve acceptable sensitivity for blood screening [31].
Inﬂuence of HBV genotype and HBsAg subtype variabil-
ity on HBsAg sensitivity was seen simultaneously, for
D⁄ayw3,E⁄ayw4, and F⁄adw4, in a total of 18 test kits. A
common motif in these three genotypes⁄subtypes seems to
be represented by the genotype speciﬁc residue 127 where
Proline (P) is changed by Threonine (T) in D⁄ayw3 and by
Leucin (L) in E⁄ayw4 and F⁄adw4. In addition, the D⁄ayw3
sample #318 includes the 118⁄128 double mutation, char-
acteristic for a naturally occurring strain distributed world-
wide [14,31,32]. In fact, the P127T change and the
T118V⁄A128V double mutation in D⁄ayw3, as well as the
P127I⁄L residue in genotypes E and F, have been reported
to be associated with reduced HBsAg reactivity [32,33].
Also, the more complex substitutions at positions 118, 127,
and 128 in D⁄ayw3 can explain the more pronounced sen-
sitivity reduction compared to one substitution at position
127 with E⁄ayw4 and F⁄adw4. Because the P127T substitu-
tion is common for D⁄ayw3 and also occurs in genotype A
subtype adw3, it may be that these subtypes can exhibit
reduced antigenicity as well. In the case of E⁄ayw4 and
F⁄adw4, there is also the genotype speciﬁc T140S residue
which has been postulated to cause conformational change
of the ‘a’ determinant [19]. In fact, in one HBsAg assay
there was a slightly reduced sensitivity (factor 2–3) with
E⁄ayw4 and F⁄adw4 but not with D⁄ayw3. The other sub-
type speciﬁc variations, including the d⁄y and r⁄w alleles
at position 122 and 160, and the subtype speciﬁc residues
at positions T126I, N131T, N134T, F143Y, A159G, Y161F,
V168A, and P178Q, appear not to be involved in reduced
antigenicity in this study. The inﬂuence of genotype and
subtype variability on the sensitivity of HBsAg assays in
the literature is somewhat inconclusive. Some investigators
report that HBV genotypes A-G can be recognized compa-
rably by commercial HBsAg assays including genotype E
[34–37]. In contrast, others found sensitivity differences
between HBV genotypes: up to 10-fold differences in the
sensitivity of three commercial assays [38]; lower binding
of anti-HBs by a factor 2–3 to ayw and adr compared to the
WHO reference adw [39]; one of 10 HBsAg kits failed to
give positive results with genotype E at 0Æ2I U⁄ml [35]; and
reduced reactivity in monoclonal antibody binding studies
for E⁄ayw4 and D⁄ayw3 [33]. The results of the 17 highly
sensitive HBsAg assays in this study essentially conﬁrm
that HBsAg kits used in the EU and Japan detect HBV geno-
types A-F with comparable sensitivity [34,35]. Moreover,
the present study shows that a substantial number (20 test
kits from around the world) had impaired sensitivity for
genotypes D⁄ayw3, E⁄ayw4 and F⁄adw4.
In addition to the genotypes⁄subtypes, there was sensi-
tivity reduction by S gene mutants in the ICBS Clinical
Panel. A total of 32 HBsAg assays showed signiﬁcant sensi-
tivity reduction with one to ﬁve HBsAg mutants. Three
HBsAg mutants identiﬁed, i.e., M133L (sample #1125),
T131I (sample #1010), and S143L (sample #1015), impacted
the sensitivity of HBsAg assays in this study as found in
previous studies [4,5,9,40]. The two other HBsAg mutations
found, P105R (sample #1135) and Q101H (sample #1039),
are outside the ‘a’ determinant and have not been reported
thus far to affect the sensitivity of commercial HBsAg
assays. Mutants S143L and Q101H could not be detected by
some HBsAg test kits. In other HBsAg test kits, there was
reduced sensitivity of different degrees (factor >2 to 100).
Nevertheless, smaller sensitivity reductions in the twofold
range yielded false negative results when close to the
assays¢ cutoff, i.e., at low HBsAg concentrations of 0Æ21–
0Æ36 IU⁄ml in mutant samples #1125 (M133L), #1135
(P105R), and #1010 (T131I). This demonstrates, once again,
the need for quantitative analysis of HBsAg sensitivity as
well as the relevance of low detection thresholds.
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ent recognition capabilities of HBsAg mutants is the assay
format, i.e., utilization of monoclonal antibodies for cap-
ture and detection phase (mono⁄mono) compared to assays
based on polyclonal antibody in the conjugate phase
(mono⁄poly) [38]. Nevertheless, in this study, there were
assays with comparable sensitivity for the HBV genotypes
tested but with deﬁciencies in detection of HBsAg mutants,
as well as assays with no sensitivity reduction for HBsAg
mutants but vulnerable to HBV genotypes⁄subtypes. For
instance, the Advia Centaur HBsAg and Ortho HBsAg
assays which have mono⁄mono test design were weak in
detecting mutant T143L but detected all HBV geno-
types⁄subtypes comparably. On the other hand, the Immu-
lite HBsAg assay had difﬁculties in detecting mutants
M133L and P105R despite having a polyclonal detection
phase [4]. Therefore, epitope recognition seems to be more
signiﬁcant for mutant detection than the assay format [9].
The worst scenario seems to be represented by those kits
that were compromised in mutant and genotype⁄subtype
detection indicating a mono⁄mono test design with
deﬁciencies in detecting epitopes in loop1 and loop 2 of the
‘a’ determinant. Generally, HBsAg test kits that include
multiple monoclonal antibodies in the capture phase
together with a polyclonal conjugate phase seem to be the
best choice to assure recognition of different HBsAg
epitopes.
Speciﬁcity evaluated on a panel of 200 negative samples
was at an acceptable level of ‡99Æ5% [8] for the majority of
HBsAg test kits (n = 57) and revealed an effective balance
between the assays sensitivity and speciﬁcity. Nevertheless,
nine HBsAg assays showed slightly lower speciﬁcities in
the range of 96Æ37–99Æ0%. Four assays were not supplied in
sufﬁcient quantity to enable speciﬁcity testing. It should be
noted that the number of 200 negative samples might be
too low for statistically ﬁrm conclusions. In order to pre-
vent loss of blood donations due to poor assay speciﬁcity
and to avoid serious operational difﬁculties because of high
rates of initial reactive non-speciﬁcities, it is recommended
to test for high assay speciﬁcity with a higher number of
negative samples, e.g. >2000 or 5000 [8], from the target
population.
In conclusion, ICBS has established well-characterized
panels for assessing the performance of HBsAg assays
including genotype⁄subtype dependent sensitivity. The
evaluation of 70 HBsAg test kits in this study revealed sig-
niﬁcant variation in diagnostic efﬁcacy. A relatively high
number of assays, including all rapid tests, were of poor
sensitivity rendering them unsuitable for HBsAg detection
at low concentrations. Therefore, these assays cannot be
recommended for use within a public health context, e.g.,
blood screening. Genetic variability in the S gene addition-
ally impaired diagnostic efﬁcacy. We hope therefore that
the results of the study would draw attention to the vari-
ability of HBsAg test kits available on the market as well
as encourage the blood transfusion services within the
resource-challenged countries to, whenever possible,
locally evaluate the assays to be introduced for blood
screening for appropriate sensitivity and speciﬁcity or to
seek for corresponding published information. In order to
expand access to high quality of assays it is also advisable
to use more than one routine batch for evaluation.
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